In addition to immune checkpoint inhibitors, OX40-stimulating antibodies have been shown to augment the effectiveness of several treatments that indirectly stimulate immune responses, including dasatinib (in a c-KIT mutant P815 mastocytoma tumor model [30], dabrafenib and trametinib (in BRAFV600E-mutant melanoma) [31], and radiotherapy [32,33,34]. The gene discussed is TNFRSF4; the disease is neoplasm.